1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,990 | 1,044 | 20.08. | |
| 1,004 | 1,034 | 20.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Moberg Pharma AB: Moberg Pharma's Interim report January - June 2026 | 114 | GlobeNewswire (Europe) | APPROVED TRADEMARK CHANGE IN THE FIRST EUROPEAN COUNTRIES AND LICENSE AGREEMENTS FOR APAC AND CHINA
SIX-MONTH PERIOD (JAN-JUN 2026)
Net revenue SEK 10.7 million (7.5)
EBITDA SEK -5.8 million (-13.1)... ► Artikel lesen | |
| 11.08. | Moberg Pharma AB: Moberg Pharma strengthens organization ahead of European launch | 204 | GlobeNewswire (Europe) | STOCKHOLM, August 11, 2026. Moberg Pharma AB (OMX: MOB) announces changes to its management team and strengthens the organization ahead of upcoming launches. The management team will be joined by two... ► Artikel lesen | |
| 30.06. | New number of shares and votes in Moberg Pharma AB (publ) | 2 | Cision News | ||
| 18.06. | MOBERG PHARMA AB: The board of directors exercises authorizations to issue and repurchase C-shares, and converts class C shares to common shares | 2 | Cision News | ||
| 15.06. | Moberg Pharma AB: Moberg Pharma reports progress on commercial launch preparations | 236 | GlobeNewswire (Europe) | STOCKHOLM, June 15, 2026. Moberg Pharma AB (publ) announces that the first European countries have approved the rebranding of MOB-015 (Terclara®) to Karo Healthcare AB's brand. The approvals provide... ► Artikel lesen | |
| 08.06. | Moberg Pharma AB: Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to China | 415 | GlobeNewswire (Europe) | STOCKHOLM, June 8, 2026. Moberg Pharma AB (publ) has entered into a license agreement with Karo Healthcare AB regarding the commercialization of the nail fungus drug MOB-015 (Terclara®) in China through... ► Artikel lesen | |
| 21.05. | Moberg Pharma AB: Bulletin from Moberg Pharma's AGM on May 21[st], 2026 | 214 | GlobeNewswire (Europe) | STOCKHOLM, May 21, 2026. Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") held its Annual General Meeting today. The Annual General Meeting resolved on, among other things, the following.
Adoption... ► Artikel lesen | |
| 12.05. | Moberg Pharma AB: Interim report January - March 2026 | 191 | GlobeNewswire (Europe) | LICENSE AGREEMENT FOR AUSTRALIA, NEW ZEALAND, SOUTH KOREA AND TAIWAN
FIRST QUARTER (JAN-MAR 2026)
Net revenue SEK 4.9 million (3.9)
EBITDA SEK -1.5 million (-3.7)
Operating profit (EBIT) SEK... ► Artikel lesen | |
| MOBERG PHARMA Aktie jetzt für 0€ handeln | |||||
| 24.04. | Moberg Pharma AB: Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to Australia, New Zealand, South Korea and Taiwan | 477 | GlobeNewswire (Europe) | STOCKHOLM, April 24, 2026. Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of the nail fungus treatment MOB-015 (Terclara®)... ► Artikel lesen | |
| 17.04. | Notice of Annual General Meeting in Moberg Pharma AB (publ) | 2 | Cision News | ||
| 13.03. | MOBERG PHARMA AB: Additional terbinafine supplier approved | 2 | Cision News | ||
| 17.02. | Moberg Pharma AB: Moberg Pharma Year-end report 2025 | 296 | GlobeNewswire (Europe) | A BREAKTHROUGH YEAR WITH A CLEAR PATH TO EUROPE
THE YEAR (JAN-DEC 2025)
Net revenue SEK 13.5 million (9.8)
EBITDA SEK -25.7 million (-23.5)
Operating profit (EBIT) SEK -27.3 million (-324.8)... ► Artikel lesen | |
| 11.11.25 | Moberg Pharma AB: Moberg Pharma interim report January - September 2025 | 258 | GlobeNewswire (Europe) | FURTHER SUCCESS FOR TERCLARA
NINE-MONTH PERIOD (JAN-SEP 2025)
Net revenue SEK 11.5 million (8.8)
EBITDA SEK -18.7 million (-15.7)
Operating profit (EBIT) SEK -19.9 million (-16.7)
Profit for... ► Artikel lesen | |
| 05.11.25 | Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential | 509 | PR Newswire | STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015... ► Artikel lesen | |
| 05.11.25 | Karo Healthcare enters an exclusive license agreement with Moberg Pharma for MOB-015 in Europe | 470 | PR Newswire | STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Karo Healthcare AB ("Karo") has entered an exclusive licensing agreement with Moberg Pharma AB ("Moberg Pharma") regarding the commercialisation... ► Artikel lesen | |
| 29.09.25 | Moberg Pharma AB: Bulletin from Moberg Pharma's Extraordinary General Meeting held on 29 September 2025 | 259 | GlobeNewswire (Europe) | STOCKHOLM, September 29th, 2025. Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") today held an Extraordinary General Meeting. The Extraordinary General Meeting resolved in accordance with... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DERMAPHARM | 39,900 | -0,99 % | DERMAPHARM lieferte solide Halbjahreszahlen | Der Umsatz stieg im ersten Halbjahr 2026 um 2,9 % auf 591,0 Mio. €, das bereinigte EBITDA um 10,3 % auf 163,2 Mio. €. Positiv stach die Margenverbesserung um 1,8 Prozentpunkte auf 27,6 % hervor. Rückenwind... ► Artikel lesen | |
| DOCMORRIS | 11,060 | +0,18 % | Ihre wichtigsten Termine: Spannende Zahlen von: Analog Devices, DocMorris, Carlsberg, Geberit & Straumann | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: US0326541051,DK0010181759,DE0007314007... ► Artikel lesen | |
| SYNBIOTIC | 0,785 | -1,75 % | EQS-Adhoc: SYNBIOTIC SE: SOLIDMIND Group GmbH und Lean Labs Pharma GmbH beabsichtigen, Anträge auf Eröffnung von Insolvenzverfahren zu stellen | EQS-Ad-hoc: SYNBIOTIC SE / Schlagwort(e): Strategische Unternehmensentscheidung/Insolvenz
SYNBIOTIC SE: SOLIDMIND Group GmbH und Lean Labs Pharma GmbH beabsichtigen, Anträge auf Eröffnung... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 78,24 | +1,69 % | Should You Hold Edwards Lifesciences Stock in Your Portfolio? | ||
| CANTOURAGE GROUP | 5,860 | 0,00 % | H1 out: Margins over sales is increasingly paying off; chg.: Cantourage Q2'26: EBITDA +45% yoy to € ... | Topic: Cantourage released Q2'26 figures showing a further step-up in earnings quality. Sales declined yoy on a deliberate exit from low-margin German volumes, while EBITDA grew 45% yoy.Q2 sales came... ► Artikel lesen | |
| BACHEM | 83,10 | +0,42 % | Bachem Holding AG H1 Sales Increase | HONG KONG (dpa-AFX) - Bachem Holding AG (BHM.F) announced earnings for first half of CHF50.3 million.The company's earnings came in at CHF50.3 million, or CHF0.67 per share. This compares with... ► Artikel lesen | |
| MEDPACE | 529,00 | +0,72 % | If You Invested $100 In Medpace Holdings Stock 5 Years Ago, You Would Have This Much Today | ||
| COSMO | 62,40 | 0,00 % | Cosmo Pharmaceuticals N.V.: Cosmo Announces SIX Ticker Symbol Change to "CMHC" | Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - August 14, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced that it will change its ticker... ► Artikel lesen | |
| UCB | 218,20 | +0,18 % | UCB H1 Profit Surges On Strong Revenue Growth; Raises Outlook | BRUSSELS (dpa-AFX) - UCB S.A. (UCBJY), a Belgium-based biopharmaceutical company, on Thursday reported sharply higher first-half profit, supported by strong revenue growth.Profit attributable... ► Artikel lesen | |
| ROYALTY PHARMA | 51,83 | 0,00 % | Dividendenbekanntmachungen (14.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADM HAMBURG AG DE0007269003 - 13,58 EUR AGCO CORPORATION US0010841023 0,3 USD 0,2602 EUR AGNT INC US30212W1009 0,05 USD 0,0433... ► Artikel lesen | |
| PERRIGO | 11,535 | -1,70 % | Perrigo Company plc: Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations | Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S. store-brand OTC and key European... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 71,40 | +0,51 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base | - The transaction supports the evolution of the Company's shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.... ► Artikel lesen | |
| LABORATORIOS FARMACEUTICOS ROVI | 59,75 | -0,25 % | Dividendenbekanntmachungen (13.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AS COMPANY SA GRS404003006 - 0,1919 EUR BANK OZK US06417N1037 0,48 USD 0,4204 EUR BEACON MINERALS LIMITED AU000000BCN0 0,1 AUD 0... ► Artikel lesen | |
| BAYER | 48,610 | -0,82 % | Bayer: Das sind aktuell die wichtigen Schlüsselzonen | Nach dem Comeback Ende Juni hat die Bayer-Aktie eine Verschnaufpause eingelegt und dabei neue technische Zonen ausgebildet. Im Mittelpunkt stehen dabei die Unterstützung an der 50-Tage-Linie sowie das... ► Artikel lesen | |
| MERCK KGAA | 138,05 | -0,22 % | Bundeskartellamt gibt Übernahme von Bio-Techne durch Merck KGaA (Darmstadt) frei | Das Bundeskartellamt hat heute die geplante Übernahme des US-amerikanischen Biotechnologieunternehmens Bio-Techne, Minneapolis, durch die Merck KGaA aus Darmstadt freigegeben. Das Vorhaben ist auch... ► Artikel lesen |
Das Unternehmen MOBERG PHARMA AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,026 Euro und damit +0,59 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOBERG PHARMA AB finden Sie auf Wallstreet Online.